Pathophysiology of [Beta]2-glycoprotein I in antiphospholipid syndrome

Since β2 -glycoprotein I (β2 GPI) was described as the major antigenic target for antiphospholipid antibodies, many studies have focused their attention to the physiological role of β2 GPI and anti-β2 GPI antibodies on autoimmune-mediated thrombosis. Studies reporting the physiological role of β2 GP...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2010-04, Vol.19 (4), p.379
Main Authors: Matsuura, E, Shen, L, Matsunami, Y, Quan, N, Makarova, M, Geske, FJ, Boisen, M, Yasuda, S, Kobayashi, K, Lopez, LR
Format: Article
Language:English
Subjects:
Angiogenesis
Antibodies
Anticoagulants
Atherosclerosis
Dentistry
Glycoproteins
Lupus
Medicine
Metabolites
Pathophysiology
Pharmaceutical sciences
Physiology
Proteins
Thrombosis
University graduates
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since β2 -glycoprotein I (β2 GPI) was described as the major antigenic target for antiphospholipid antibodies, many studies have focused their attention to the physiological role of β2 GPI and anti-β2 GPI antibodies on autoimmune-mediated thrombosis. Studies reporting the physiological role of β2 GPI have been numerous, but the exact mechanism of action(s) has yet to be completely determined. β2 GPI"s epitopes for anti-β2 GPI autoantibodies have been characterized, however, not all of the heterogeneous anti-β2 GPI antibodies are pathogenic. The pathophysiologic role of β2 GPI has been reported in the fields of coagulation, fibrinolysis, angiogenesis, and atherosclerosis. Our understanding of the impact of β2 GPI, its metabolites and autoantibodies to β2 GPI on these physiological functions may contribute to the development of better therapeutic strategies to treat and prevent autoimmune-mediated atherothrombotic vascular disease. Lupus (2010) 19, 379--384. [PUBLICATION ABSTRACT]
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203310361352